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Abstract
The efficient induction of CD8 T cell immunity is dependent on the processing and presentation of antigen on MHC class I
molecules by professional antigen presenting cells (APC). To develop an improved T cell vaccine for HIV we investigated
whether fusing the ubiquitin gene to the N terminus of the HIV gag gene enhanced targeting to the proteasome resulting
in better CD8 T cell responses. Human monocyte derived dendritic cells (moDC), transduced with adenovirus vectors
carrying either ubiquitinated or non-ubiquitinated gag transgene constructs, were co-cultured with autologous naı¨ve T cells
and T cell responses were measured after several weekly cycles of stimulation. Despite targeting of the ubiquitin gag
transgene protein to the proteasome, ubiquitination did not increase CD8 T cell immune responses and in some cases
diminished responses to gag peptides. There were no marked differences in cytokines produced from ubiquitinated and
non-ubiquitinated gag stimulated cultures or in the expression of inhibitory molecules on expanded T cells. However, the
ability of moDC transduced with ubiquitinated gag gene to upregulate co-stimulatory molecules was reduced, whilst no
difference in moDC maturation was observed with a control ubiquitinated and non-ubiquitinated MART gene. Furthermore
moDC transduced with ubiquitinated gag produced more IL-10 than transduction with unmodified gag. Thus failure of gag
ubiquitination to enhance CD8 responses may be caused by suppression of moDC maturation. These results indicate that
when designing a successful vaccine strategy to target a particular cell population, attention must also be given to the
effect of the vaccine on APCs.
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Introduction
The urgency for a prophylactic HIV vaccine is evident by the
sustained global increase in HIV-1 infection. Despite the best
efforts of over 20 years of research an effective HIV vaccine
remains elusive, compounded by the diversity of the virus and its
ability to evade immune responses. Although HIV-1 infection
induces a strong antibody response, many of the antibodies are
unable to neutralise the broad range of strains that now exist [1].
Recent progress has been in isolating broadly neutralising
antibodies from HIV infected individuals. However such antibod-
ies only appear after infection for several years with high virus
loads and require very extensive changes in germ line immuno-
globulin changes which will be difficult to achieve with vaccina-
tions [2]. Nevertheless, induction of effective neutralising antibod-
ies remains at the forefront of developing a preventative vaccine
that provides long term immunity. However, promising studies
have implicated the importance of CD8 T cells in controlling HIV
replication, and current research is now focusing on targeting CD8
T cells to develop a sterilising vaccine [3–8]. In chronically HIV-
infected individuals CD8 T cells are found to respond to a variety
of HIV proteins and it has been shown that responses to the gag
protein, a more highly conserved HIV protein, correlated with
reduced viral loads, with an increase in breadth of gag responses
appearing to further enhance control of viral replication [5]. Thus
current studies aim to develop vaccines that recognise multiple
CD8 T cell epitopes to HIV proteins and previous work has shown
that modifying the gag protein increased CTL responses [9].
Although antigenic proteins usually contain numerous potential
CD8 epitopes there is an immunodominant hierarchy such that in
acute infections or vaccination there are responses to only one or
two epitopes [10]. Consequently, in HIV, the T cell response is
characterised by restricted breadth, usually one of two epitopes
[11] in the acute phase which broadens at the chronic stage
[12,13]. Generation of cytotoxic T cells (CTL) is dependent on the
presentation of peptides bound to the MHC class I molecules on
the surface of antigen presenting cells and levels of MHC class I
peptide complexes is a factor in determining the immunodominant
hierarchy [10]. The proteasome is the main proteolytic organelle
in the generation of MHC class I peptides [14] and proteins are
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targeted to the proteasome for degradation through a process of
ubiquitination where ubiquitin is added to lysine residues by a
series of ligases [15,16]. Ubiquitination thus plays a key role in
MHC class I presentation [17] and it has been previously shown
that ubiquitinating a transgene enhances Class I presentation and
consequently CD8 T cell responses and observed when the
transgene is delivered in an Ad5 vector or by DNA immunisation
[18,19].
Dendritic cells (DC) are the most potent antigen presenting cells
also having the unique ability to effectively stimulate naı¨ve T cells
and thus are essential for the induction of primary T cell responses
and targets for effective vaccines [20]. There are two main types of
DC, plasmacytoid DC and myeloid DC, but the latter is thought
to be primarily responsible for inducing T cell responses to
infections and vaccines. There are several distinct populations of
myeloid DC in both mouse and human [21] and for this study we
chose to investigate our vaccine constructs using human mono-
cyte-derived DC (moDC). In vivo moDC are regarded as
inflammatory DC [22,23] and thus may serve to augment an
already initiated response. Monocyte derived DC have been used
in therapeutic vaccines for cancer [24,25] and for SIV [26] and
HIV infection [27]. Based on previous work showing that CD8 T
cell responses to the HIV gag protein resulted in control of viral
replication, we hypothesised that targeting HIV gag to the DC
proteasome would result in increased MHC class I peptide
presentation and enhance the magnitude and breadth of CD8 T
cell responses. We generated an Adenovirus vector containing a
ubiquitinated gag transgene and explored T cell responses
stimulated by transduced moDC. We find that although fusion
of ubiquitin to gag promotes its proteasomal degradation, T cell
responses induced by transfected moDC are reduced and may
reflect impaired up-regulation of co-stimulatory molecules and
increased Il-10 production caused by the ubiquitin-gag fusion
vaccine.
Materials and Methods
Ethics Statement
Ethical approval was obtained from the Riverside Research
Ethics Committee and informed written consent was obtained
prior to patient blood collection.
All in vivo procedures were performed in accordance with
United Kingdom Home Office regulations and Kings College
London Ethics Committee.
Blood Samples
Peripheral blood mononuclear cells (PBMCs) were isolated from
blood leukocyte cones (National Blood Transfusion Service, UK)
or from HIV-1+ patients attending Chelsea and Westminster
hospital (London, UK), by density gradient centrifugation with
LymphoprepTM 1077 (PAA Laboratories, GmbH, UK) followed
by a 50% Percoll (Sigma, UK) gradient to obtain a high-density
fraction enriched in lymphocytes and a low-density fraction
enriched in monocytes. Fractions were aliquoted and stored in
liquid nitrogen until required.
HLA-A*0201 donors were used for the MART experiments and
were determined by firstly identifying HLA-A*02 positive individ-
uals by staining donor PBMC (National Blood Transfusion
Service, UK) with an anti-HLA-A*02 antibody and then analysing
by flow cytometry. Once identified, cells were stained with an APC
pentamer expressing the dominant peptide to the MART protein
[ELAGIGILTV, Peprotech, UK], which is recognised by HLA-
A*0201 individuals, and analysed by flow cytometry. Cells from
MART+ donors were then stored in liquid nitrogen until required.
Generation of Dendritic Cells
Monocyte derived dendritic cells (moDCs) were isolated from
the monocyte rich fraction by magnetic bead separation using
anti-CD14 coated magnetic beads (Miltenyi Biotec). Purified
monocytes were cultured in complete medium (RPMI containing
10% FBS, 100 IU/mL penicillin, 0.1 mg/mL streptomycin, and
2 mM L-glutamine; Sigma-Aldrich) supplemented with GM-CSF
(100 ng/mL) and IL-4 (50 ng/mL; R&D Systems), which was
replenished every other day. On day 7, immature DCs were
harvested, washed twice and resuspended in serum-free RPMI-
1640 prior to transduction with Ad5 vectors. Fresh moDCs were
generated on a weekly basis to boost expanding T cell cultures for
a minimum of 3 to 4 weeks.
Ad5 Gene Strategy
In this work we used mammalian codon-optimized full length
gag domain from HIV-1 Clade C isolate CN54, (encoding the
same sequence as the gag gene in a vaccine construct used
previously in the EuroVacc 02 trial [28]) and a molecular clone for
gag from HIV-1 Clade C ZM96 (a kind gift from Dr Beatrice
Hahn, University of Alabama). Gag-protein was expressed by E1/
E3 deleted replication incompetent Adenovirus 5 vectors in two
versions: 1) as Gag alone and 2) with Ubiquitin fused to the N-
terminus of Gag in which the terminal Glycine of ubiquitin has
been changed to Valine to prevent cleavage by Ubiquitin
hydolases. The two constructs were sequence verified by GeneArt
(Regensburg, Germany) and protein translation was verified by
Western blotting.
Ad5-CMV-MART-1
The MART-1 gene was a kind gift from Dr Lisa Butterfield [29]
and came in a standard VR1012 vector. The MART-1 gene was
cloned via pcDNA3.1(2) (NotI and BmHI) into the pShuttle-CMV
(NotI and HindIII). The virus was generated using the AdEasy
protocol [30] which was then purified using the Adenopure Kit
(Puresyn Inc.).
Ad5-CMV-1xUbG76VMART-1
A pcDNA3.1(+) plasmid vector carrying tetra Ubiquitin with a
Glycine to Valine mutation in position 76 at the N-terminus and
an HA tag at the C-terminus was used for construction of the
ubiquitinated MART-1 constructs. The MART-1 gene was
amplified by PCR using the VR1012-MART-1 as template. The
59primer had an incorporated KpnI site and 39primer an EcoRI site.
These sites were used to clone the PCR-amplified gene into
pcDNA3.1(+)4xUbG76V-HAtag. Three of the 4 Ubiquitin
moieties were removed with XhoI digestion resulting in
pcDNA3.1(+)1xUbG76V-MART-1-HA. 1xUbG76V-MART-1-
HA was lifted from the pcDNA(+) vector and inserted into the
pShuttle CMV using SalI and HindIII enzymes. The viruses were
made and purified as described for Ad5-CMV-MART-1.
Transduction of DCs with Ad5 Vectors
DCs were transduced with different Ad5 vectors at a ratio of
5000 virus particles (measured using the Quant-it PicoGreen assay
kit, Invitrogen) of Ad5 virus per cell for 1 hr at 37uC. Cells were
harvested and resuspended at a final concentration of 105 cells/
mL in culture medium (RPMI-1640 supplemented with 5%
pooled human AB serum (Sigma Aldrich, UK), 1% penicillin, 1%
streptomycin and 1% L-glutamine (PAA Laboratories)). Cells were
incubated overnight then matured the following day with bacterial
lipopolysaccharide (LPS, 1 mg/ml, Sigma Aldrich) and IFNc
(1000 U/ml, Miltenyi Biotec) for a further 24 hrs.
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To assess proteasomal degradation of targeted vaccine genes,
DCs were transduced with the different Ad5 vectors for 24 hrs,
and following maturation were cultured in the presence or absence
of a 10 mM of a proteasomal inhibitor, MG132 (Sigma-Aldrich,
UK) for a further 24 hrs.
To assess the impact of transduction on the maturation of DCs,
DCs were transduced with the different Ad5 vectors for 24 hrs,
matured with LPS and IFNc for a further 24 hrs and then surface
stained for anti-CD80-PE (clone 2D10, BioLegend), anti-CD83-
FITC (clone HB15e, BD UK), anti-CD86-APC (clone IT2.2,
BioLegend), anti-HLA-DR-PECy5 (clone G46-6, BD, UK) and
anti-PDL1-FITC (clone MIH2, AbD Serotec).
Isolation of Naı¨ve T Cells
Autologous naı¨ve T lymphocytes were isolated from the
lymphocyte rich fraction by negative selection by firstly enriching
for T cells using the Pan T cell isolation kit II (Miltenyi Biotec)
followed by depletion of CD45RO memory T cells using anti-
CD45RO coated magnetic beads (Miltenyi Biotec) according to
the manufacturer’s instructions. Purity of isolated cells was greater
than 90% as determined by flow cytometry.
Cell Culture
Purified naı¨ve T lymphocytes were cultured with transduced
moDCs in culture medium and on day 7 and every other
subsequent day thereafter during culture they were supplemented
with IL-2 (50 U/ml), IL-15 (2.5 ng/ml) and IL-7 (10 ng/ml). Cells
were harvested weekly, counted, viability assessed by Trypan Blue
(Sigma-Aldrich, UK) exclusion and resuspended at a concentra-
tion of 26106 cells/mL. They were then co-cultured with a new
batch of autologous Ad5-transduced mature DCs at a ratio of 20:1
in culture medium supplemented with the aforementioned
cytokines. T cells were stimulated with transduced moDC three
or four times to expand antigen specific T cells.
To assess T cell responses, cells were restimulated with peptides
(NIBSC, UK) spanning the gag protein either individually or in
pools as indicated in the Results, and were used at a final
concentration of 1 mg/ml.
Mice and Immunisation
C57BL/6 mice were purchased from Harlan, UK, and 6–8
week old female mice were used in experiments. Mice were
immunised with 1010 VP of either gag construct subcutaneously as
described previously [31]. All in vivo procedures were performed in
accordance with Institutional and United Kingdom Home Office
regulations for animal experimentation. Immunisations were
carried out under anaesthesia using best practice.
IFNc ELISpot
HIV gag-specific IFNc T cell responses were determined by
restimulation of human T cells or, 7 day post injection mouse
splenocytes, with gag overlapping peptides (15-mers overlapping
by 11aa, NIBSC, UK) and quantified by an ELISPOT assay (anti-
human IFNc ELISPOT, Mabtech AB, Sweden or anti-mouse
IFNc ELISpot, U-CyTech, The Netherlands) according to the
manufacturer’s instructions with the following modification to the
human ELISpot protocol. After incubation with the secondary
antibody, plates were washed and ABC peroxidase-avidin-biotin
complex (Vector labs, UK) was added for 1 h at room
temperature. Spots were then developed by addition of filtered
AEC (Sigma Aldrich, UK) substrate solution for 4 min. Develop-
ment was stopped with water and the plates were dried overnight
before being read using an automated AID ELISPOT reader
(AutoImmun Diagnostika, Germany). Mouse ELISpot plates were
read on a Bioreader 5000 (Bio-Sys, Germany).
Intracellular Cytokine Staining
After 3–4 weeks of T cell expansion, cells were harvested,
washed twice and rested in cytokine-free culture medium for
48 hrs. Following this time, cells were washed, recounted and
seeded in 96 well plates at a density of 106 cells/100 ml. DC, which
were transduced with the different Ad5 vectors as previously
indicated and were matured overnight with LPS and IFNc, were
co-cultured with the T cells at a ratio of 1:10. 121 individual HIV-
CN54 gag overlapping peptides (15-mers overlapping by 11aa,
NIBSC, UK) were pooled into 22 pools such that each pool
contained 11 peptides and each peptide was present in 2 pools.
Each pool was then added to wells in duplicate at a concentration
of 11 mg/ml. Negative control wells consisted of cells cultured in
the absence of peptides but in the presence of 0.025% dimethyl
sulfoxide (DMSO, Sigma Aldrich, UK). Phorbol 12-myristate 13-
acetate (PMA, 50 ng/ml, Sigma Aldrich, UK) and ionomycin-
(1 mg/ml, Sigma Aldrich, UK) stimulated cells served as a positive
control. Cells were incubated for 1 hr at 37uC, after which time
Brefeldin A was added (10 mg/ml, Sigma Aldrich, UK) and cells
were incubated for a further 5 hrs at 37uC. After this time, cells
were harvested and surface stained for 20 minutes at 4uC with
anti-CD8-APC H7 (clone SK1), and CD3-Percp-Cy5.5 (clone
SK7), (both from BD Biosciences, UK). Cells were washed, fixed
and permeabilised with the BD Cytofix/Cytoperm kit (BD
Biosciences, UK) according to the manufacturer’s instruction.
Following permeabilisation, cells were stained for 30 minutes at
room temperature with an anti- IFNc -PE-Cy7 antibody (clone
4S.B3, eBioscience, UK), anti-TNF-a-FITC (clone 6401.1111, BD
Bioscience, UK) or anti-IL10-PE (clone JEs3-19F1, BD Biosci-
ence, UK) or in combination. Finally, cells were washed and fixed
with BD stabilising fixative (BD Biosciences, UK). Cells were
acquired using a 3-laser configuration LSRII flow cytometer (BD
Biosciences, USA). Cytokine secretion by antigen specific T cells
were analysed by FlowJo (Tree Star Inc, USA). The gating strategy
for the Identification of T cells was performed as previously
published in [32].
IL-10 ELISA
Using a standard ELISA protocol and matched antibody pairs,
levels of IL-10 were determined in culture supernatants. Briefly, 96
well plates (Nunc, UK), were coated with 4 mg/ml of human anti-
IL-10 monoclonal antibody (R&D Systems, UK). Following an
overnight incubation at 4uC, plates were washed and blocked with
200 mL of StartingBlockTM (Thermo Scientific, UK) for 30 mins
at room temperature. Blocking buffer was removed, and without
washing, supernatants were added to the plates along with
cytokine standards ranging from 4000 pg/mL to 62.5 pg/mL
and incubated for a minimum of 2 hrs at room temperature. Plates
were then washed and incubated with 0.5 mg/mL of anti-IL-10
biotinylated antibody (R&D Systems, UK) for 1 hr at room
temperature. Plates were washed and incubated with 0.1 mg/mL
of Strepavidin peroxidise (High Sensitivity, PIERCE, UK) for
30 mins at room temperature. Following a final wash, TMB
substrate (Sigma, UK), was added and the reaction was stopped
with Stop Solution (Sigma, UK). Plates were read using an ELISA
plate reader at 450 nm.
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Immunogenicity Assessment of Gag Vectors in
Lymphocytes from HIV-1-infected Individuals
40–60 ml of blood was collected from three aviremic HIV-1
infected patients receiving highly active anti-retroviral therapy.
Ethical approval was obtained from the local Ethics Committee
and written informed consent was obtained from all patients. The
samples were processed as described by [33] with slight
modification. In brief, PBMC were isolated and rested overnight
at 4uC in complete medium supplemented with 2% Hepes (Sigma
Aldrich, UK). Monocytes were positively isolated using CD14
micro-beads (Miltenyi Biotec, UK) and the remaining cells were
cryopreserved at in liquid nitrogen. DC were generated from
monocytes over seven days as previously indicated then trans-
duced with either Ad5 expressing non-ubiquitinated gag (Ub2gag)
or ubiquitinated gag (Ub+gag). Cells were matured with LPS and
IFNc overnight then co-cultured with autologous thawed PBMC
for 7 days at a ratio of 1:10. HIV gag-specific IFNc T cell
responses were quantified by ELISPOT assay as described above.
A pre-culture period in the presence of transfected DC was used as
the T cell response has been noted to wane in individuals receiving
antiviral therapy [34] and we wished to detect responses to low
frequency sub dominant epitopes. Cultured ELISPOTS have been
shown to increase the sensitivity of detection for T cell responses
[35].
Flow Cytometry
Prior to co-culture with transduced DCs, 106 T cells were
harvested, washed and stained with anti-CD8-APC.H7 (clone
SK1), anti-CD3-Percp-Cy5.5 (clone SK7), anti-PD-1-APC (clone
MIH4), anti-CD38-FITC (cloneHIT2) (all from BD Bioscience,
UK), anti-CD160-PE (clone 688327), anti-TIM3-PE (clone
344823)(both from R&D, UK) and anti-LAG3-FITC (clone
17B4, Enzo Life Sciences, UK) for 20 mins at room temperature.
Following this incubation, cells were washed and fixed with BD
stabilising fixative (BD Biosciences). One hundred thousand cells
were acquired within a live gate using a 3-laser configuration
LSRII flow cytometer (BD Biosciences, USA) and analysed by
FlowJo (Tree Star Inc, USA).
To assess gag protein production, transduced DCs were
harvested, washed and stained with anti-gag-PE (clone KC57,
Beckman Coulter UK) for 20 mins at room temperature.
Following this incubation cells were washed and fixed with BD
stabilising fixative (BD Biosciences) and cells were acquired on a
forward scatter versus PE plot using a 3-laser configuration LSRII
flow cytometer (BD Biosciences, USA) and analysed by FlowJo
(Tree Star Inc, USA).
Statistics
Data are expressed as mean6standard deviation unless
otherwise stated and were analysed by GraphPad Prism Version
5.00. When more than 2 groups were compared, statistical
significance was determined using Friedman Test with Dunn’s
Multiple comparison post test, or a paired t test when two groups
were compared. Statistical significance was determined at p,0.05.
Results
Fusion of Gag to Ubiquitin Enhances Proteasomal
Targeting
To demonstrate that fusion to ubiquitin enhances targeting to
the proteasome, transduced cells were incubated in the presence or
absence of the proteasomal inhibitor MG132. In the absence of
inhibitor the percentage of cells expressing CN54 gag ranged from
1.8 to 4.5% (mean = 2.74, SD = 1.52), for the non-ubiquitinated
gag (CN54 0x) and 0.65 to 1.33% (mean = 0.96, SD = 0.34) for the
ubiquitinated gag (CN54 1x) constructs (p = 0.105) (Figure 1A). In
the presence of the inhibitor, expression was significantly increased
in moDC transduced with either construct, with 20.7%–41.9% of
CN54 0x and 33.1%–55.4% of CN54 1x transduced cells
expressing gag (Figure 1A and B). However, the increase in
expression was significantly more marked for the CN54 1x with a
44-fold increase compared to a 12.5 fold increase for the CN54 0x
constructs. Thus fusion with ubiquitin does increase proteasomal
degradation and, as noted previously [36], the overall expression
level was higher for the ubiquitin fusion gene. In addition to the
frequency of gag+ cells, the density of gag was determined by
analysing the mean fluorescence intensity (MFI). The results in
Figure 1D mirrored those observed in Figure 1A, with an increase
in gag density when MG132 was added.
In addition to assessing the production of the gag protein, we
also determined whether there was any difference in the viability
and expansion of cells transduced with the constructs. Using
Trypan blue exclusion there was no significant difference between
the two constructs in terms of cell viability or the ability to expand
cells (Figure 1C).
Absence of Enhanced Responses in Ubiquitinated Protein
Previous work has shown that ubiquitination of a desired
protein not only increased the expression of the protein but also
the T cell responses to the protein [36,37]. Results from Figure 1A
showed that in the absence of a proteasome inhibitor, there was
low expression of gag from cells treated with either the non-
ubiquitinated (Ub2) or ubiquitinated (Ub+) gag constructs (1.8–
4.5% and 0.65–1.33% respectively) but that in the presence of the
inhibitor a high frequency of gag+ cells was detected (20.7–41.9%
for Ub2gag vs 33.1–55.4% for Ub+gag), suggesting that unmod-
ified CN54 gag is efficiently targeted to the proteasome and
increased by fusion to ubiquitin. To determine whether targeting
the gag protein to the proteasome translated to enhanced CTL
responses, we assessed the ability of DCs transduced with the
vectors to stimulated production of IFNc by T cells from HIV-
infected donors (Figure 2A). Despite the efficient proteasomal
targeting of both constructs, IFNc production was stimulated in
lower numbers of T cells in cultures transduced with the Ub+gag
constructs (Figure 2A). As we could not rule out the possibility that
these findings may reflect dysfunctional cellular immunity of HIV-
infected individuals we evaluated both constructs in an in vivo
mouse model and, in a primary in vitro stimulation system using
cells from healthy controls. Similar to the investigations with cells
from HIV-infected individuals, we observed consistently lower T
cell responses in the in vivo mouse model (Figure 2B) and in T cells
stimulated with moDC transduced with the Ub+gag construct
(Figure 2C). To evince which cell type was responsible for IFNc
production, ICS was also performed and Figures 2D and E show
that both CD8 and CD4 T cells produced the pro-inflammatory
cytokine and that there were fewer cytokine producing cells
stimulated with Ub+gag constructs.
Reduced T Cell Responses Induced by Ubiquitin Fused to
a More Stable Gag Protein
Unmodified CN54 gag is relatively unstable with most of the
protein degraded by the proteasome as shown (Figure 1A). Thus
enhancement of already high levels of proteasomal degradation by
fusion with ubiquitin may have a negative rather than a positive
effect on presentation. To determine whether the findings reflect
the stability of CN54 gag, Ad5 vectors were made coding for
unmodified and ubiquitin fused gag from the Clade C virus ZM96.
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When moDC were transduced with Ub2ZM96 gag vectors there
was a high level of gag expression, approximately 70% (Figure 3A),
with only a little increase in the presence of the proteasomal
inhibitor as indicated by a slight increase in MFI on FACS analysis
(data not shown). Thus ZM96 gag is inherently more stable than
CN54 gag. There was a marked reduction in the level of gag
expression (13%) in moDC transduced with the Ub+ construct
which was increased to 62% (Figure 3A) in the presence of the
proteasomal inhibitor with a significant increase in MFI (data not
shown). When the immunogenicity of the two constructs was
tested in the in vitro priming assay, in general lower responses were
obtained with the Ub+ construct against individual peptides
(Figure 3B). Overall fusion with ubiquitin lowered the response
although responses to 7 peptides were increased. For the 3 donors
Figure 1. Expression of constructs and T cell expansion. A, B and D) Human moDCs were transduced with either the non-ubiquitinated (0x) or
ubiquitinated (1x) HIV-1 CN54 gag constructs for 24 h or untransduced (control) and then cultured for a further 18 h in the presence (grey bar) or
absence (hatched bar) of the proteasome inhibitor, MG132 (A and B). Cells were then harvested and stained intracellularly with anti-gag-PE antibody
and analysed for the frequency (A) and density (B) of gag by flow cytometry. Results shown are the mean6SD for 3 donors and representative flow
cytometry plots are shown in D. C) MoDCs were transduced with either the non-ubiquitinated (0x, closed circle) or ubiquitinated (1x, closed square)
HIV-1 CN54 gag constructs and co-cultured with autologous naı¨ve T cells. On a weekly basis, cells were harvested and counted by Trypan blue
exclusion and co-cultured with freshly transduced moDCs. Graph shows the mean6SD of 4 donors.
doi:10.1371/journal.pone.0088327.g001
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not shown, only 2/49, 5/49 and 1/49 peptides gave a better
response with the Ub-gag. Our CN54 gag construct lacked the
myristolation site at the N terminus and to rule out the possibility
that this may have accounted for the CN54 vector findings CN54
constructs with an intact myristolation site were made and tested.
The results with these vectors were identical to constructs lacking
the myristolation site (data not shown). Taken together with the
ZM96 gag results, these findings suggest that it is the fusion of gag
Figure 2. IFN gamma production by T cells treated with gag constructs. MoDCs were transduced with either the non-ubiquitinated (0x,
hatched bar) or ubiquitinated (1x, grey bar) HIV-1 CN54 gag constructs and co-cultured for 7 days with autologous T cells for cells from A) HIV
infected patients or C) for healthy control donors. T cells were expanded in culture for 4 weeks, harvested and restimulated with peptide pools and
IFNc production determined by ELISPOT. In addition, mice were injected with either construct and one week post injection, spleens were harvested,
stimulated with peptide pools and IFNc production was determined by ELISPOT (B). IFNc production by T cells from healthy human controls was also
determined by intracellular cytokine staining of CD8 or CD4 T cells (D and E). Graph A) represents one donor of 36 SD, B) represents 3 mice6SD and
is representative of one experiment out of three, C) represents 2 individual donors out of 6, D) represents 4 donors6SD and E) is a representative
CD8+ intracellular flow cytometry plot.
doi:10.1371/journal.pone.0088327.g002
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to ubiquitin rather than excessive degradation of gag that reduces
the level of responses.
Ubiquitination does not Inhibit Production of Immune
Mediators
To determine whether ubiquitination influenced the production
of other immune mediators, supernatants were collected during
the course of co-culture of DCs with T cells and the production of
10 immune mediators was determined. The production of IL-1a,
IL-1b, MIP-1a, TNF-a, IL-6, IL-10, IL-13, IL-4, Granzyme A,
and Granzyme B was detected at all time points during in vitro
culture, although there were no significant differences in
production of mediators in supernatants between the two
transgene constructs (Figure 4A). To determine whether there
were any differences at an epitope level, the expression of TNF-a
and IL-10 were measured by ICS. The results in Figure 4B show
that there were some differences at an epitope level but that overall
there was no significant difference between the expression of either
TNF-a or IL-10 between the two constructs.
Ubiquitinated Gag Stimulation does not Preferentially
Increase Inhibitory Molecule Expression on T Cells
To assess whether the difference in IFNc production between
cells co-cultured with either construct was due to differences in
CD8 and CD4 T cell phenotype, a panel of inhibition and
activation markers was investigated (Figure 5). The frequency of
CD8 T cells increased during the course of culture while there was
a concomitant decrease in the frequency of CD4 T cells (Figure 5A
and B respectively). All markers increased in frequency on both T
cell subsets during the course of the in vitro culture and there was
no significant difference between cells that had been stimulated
with either the Ub+gag or Ub2gag constructs (Figure 5).
Absence of Enhanced Immune Responses to
Ubiquitination is a Consequence of the Gag Insert
To determine whether the absence of enhanced responses to the
Ub+gag construct was due to the ubiquitination of the gag protein,
another model ubiquitinated system was used to examine CD8 T
cell responses. Melanin A, a melanoma protein, is recognised by
Figure 3. Expression of constructs and T cell responses. A) Human moDCs were transduced with either the non-ubiquitinated (0x) or
ubiquitinated (1x) HIV-1 ZM96 gag constructs for 24 h or untransduced (control). Cells were then cultured for a further 18 h in the absence (hatched
bar) or presence (grey bar) of the proteasome inhibitor, MG132. Cells were then harvested and stained intracellularly with anti-gag-PE antibody and
analysed by flow cytometry. Results shown are mean6SD for 3 donors. B) MoDCs were transduced with either the non-ubiquitinated (0x, hatched
bar) or ubiquitinated (1x, grey bar) HIV-1 ZM96 gag constructs and co-cultured with autologous naı¨ve T cells. After 4 weeks of T cell expansion in
culture, T cells were harvested and restimulated with single individual peptides and IFNc production was determined by ELISPOT. Overall fusion with
ubiquitin lowered the response although responses to 7 peptides were increased. For the 3 donors not shown only 2/49, 5/49 and 1/49 peptides
gave a better response with Ub-gag. Graph represents 1 of 4 donors.
doi:10.1371/journal.pone.0088327.g003
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Figure 4. Detection of immune modulators in supernatants of cultures, or by ICS, treated with either construct. MoDCs were
transduced with either the non-ubiquitinated (0x, hatched bar) or ubiquitinated (1x, grey bar) HIV-1 CN54 gag constructs and co-cultured with
autologous naı¨ve T cells. After each week, supernatants were removed and the presence of the indicated cytokines was determined by CBA and
analysed by flow cytometry (A). After 4 weeks in culture, the cells were harvested and restimulated with peptide pools and the expression of TNF-a
and IL-10 were determined by ICS. The box plots (A) represent the median with upper and lower quartiles, and whiskers represent the min and max
values of 5 donors. Graph B show the results of 4 donors6SD.
doi:10.1371/journal.pone.0088327.g004
Figure 5. Phenotype of CD8 and CD4 T cells stimulated with either non-ubiquitinated or ubiquitinated constructs. MoDCs were
transduced with either the non-ubiquitinated (0x, hatched bar) or ubiquitinated (1x, grey bar) HIV-1 CN54 gag constructs and co-cultured with
autologous naı¨ve T cells. After each subsequent week in culture, cells were removed and stained with antibodies to A) CD8 or B) CD4 and the
indicated surface markers. Cells were analysed by flow cytometry, and the box plots represent the median with upper and lower quartiles, and
whiskers represent the min and max values of 9 donors.
doi:10.1371/journal.pone.0088327.g005
HIV Gag Modification Impairs T Cell Priming
PLOS ONE | www.plosone.org 9 February 2014 | Volume 9 | Issue 2 | e88327
an unusually high number (1:2,500 or greater) of naı¨ve CD8 T
cells in HLA-A*02 restricted individuals [38]. The dominant
peptide of MART, ELAGIGILTV, is recognised by naive CD8 T
cells from HLA-A*0201 individuals and readily detectable by
pentamer labelling. We identified HLA-A*0201 donors with CD8
cells that were positive for MART pentamer staining and
stimulated moDCs with either a ubiquitinated MART (Ub+-
MART) or non-ubiquitinated MART (Ub2MART) construct.
The number of pentamer positive cells generated by the vector
transduced moDC increased to 2–3% over the first week of culture
but did not increase in number over the following weeks
(Figure 6A). Stimulation with peptide pulsed moDC expanded
slightly higher numbers of MART-specific CD8 T cells and there
was an increase in the expression of CD38, TIM3, PD1, CD160
and LAG1 over the course of the stimulation period (Figure 6A).
Interestingly, there was no significant difference in the frequency
of CD8 MART-specific T cells generated by the two constructs.
To determine whether the ubiquitination of MART affected the
expression of IFNc by CD8 T cells, CD8 T cells were expanded in
the presence of either Ub+ or Ub2 MART constructs and after 3
weeks, cells were harvested and expression of IFNc was measured
by intracellular cytokine staining or ELISPOT in the total CD8
population. (It was not possible to detect IFNc in pentamer+ cells
following Brefeldin A addition, as our staining protocol occurred
after stimulation and were not detectable [39]). Unlike the gag
transgene experiments, there was no difference in the level of IFNc
by CD8 T cells induced by the Ub+ or Ub2 transgene constructs
(Figure 6B).
Ubiquitinated Gag Suppresses Upregulation of Dendritic
Cell Co-stimulatory Molecules
Results from our MART experiments showed that ubiquitina-
tion of proteins, in principle, should not reduce immune responses
but as previously shown, should in some cases increase responses.
Phenotypic characterisation of responding T cells showed that
there were no differences between T cells stimulated with DCs
transduced with either Ub2gag or Ub+gag constructs (Figure 5).
Consequently, we investigated whether transduction of the
moDCs with either construct affected DC maturation. Expression
of CD86, CD80, CD83 and HLA-DR were significantly reduced
in DCs, stimulated to mature with LPS and IFNc, after
transduction with Ub+gag compared to Ub2gag constructs
(Figure 7A). There was no significant difference in viability
between the transduced DCs (p = 0.888, data not shown). To
elucidate whether the decrease in co-stimulatory molecules was
specific to gag ubiquitination, we transduced DCs with our other
constructs, Ub2MART and Ub+MART. Unlike the gag transgene
constructs, there was no difference in the expression of any of the
maturation markers between the Ub+ and Ub2 MART transgene
constructs (Figure 7B). There was no difference in the frequency of
DCs expressing the apoptotic ligand, PDL1 (Figure 8A) but a
significantly higher fold increase in the amount of IL-10 in culture
supernatants of DCs transduced with Ub+ gag (Figure 8B). This
was in contrast to the expression of IL-10 by T cells which showed
no difference in the percentage of cells expressing IL-10 in
response to either construct (Figure 4). These results suggest that
Ub+ gag influences T cell responses by impinging on DC
maturation and is a property specifically associated with fusion
of ubiquitin to HIV gag.
Discussion
The ability to increase the magnitude and repertoire of CTLs to
HIV-1 proteins has been at the forefront of HIV vaccine
development for a number of years. Previous studies have shown
that control of virus load is correlated not only to specific HIV
proteins, namely gag, but more importantly to the breadth of the
response [5] and subsequently studies have focused on increasing
the magnitude and repertoire of T cell responses. The investiga-
tion into whether ubiquitination of the gag protein would yield
enhanced CTL responses has been driven by previous work, which
has illustrated the effectiveness of such a strategy. Modified DNA
vaccines, and one report using an Ad5 deliver vector, which have
incorporated a ubiquitin gene to increase targeting to the
proteasome, and hence increasing the antigenic peptides to the
MHC class I pathway have proved fruitful in many models
[18,40,41]. Indeed, modification of the HIV gag protein in a
murine in vitro model also indicated improved CTL responses [9].
However, our initial experiments investigating the expression and
targeting of our transgene construct to the proteasome indicated
that in the absence of ubiquitin, the CN54 gag is targeted readily
to the proteasome and that the addition of ubiquitin further
enhanced degradation. The question then arose as to whether the
already efficient targeting of the CN54 gag to the proteasome
resulted in enhanced epitope responses as a consequence of
ubiquitination. Despite IFNc responses to the non-ubiquitinated
transgene construct, ubiquitination of the transgene did not
enhance IFNc production nor did it result in a broader response
by CTLs, though in some donors the recognition of the odd
epitope was enhanced by the ubiquitinated transgene (Figure 3B).
Generally the magnitude of the response was reduced for both
dominant and subdominant epitopes rather than total loss of all
subdominant epitopes. This may reflect the in vitro priming
system where a high ratio of antigen presenting cells (APC) to T
cells is maintained throughout the culture and thus less likely to
limit competition between T cells recognising dominant and
subdominant epitopes on the surface of the APC. Overall,
however, there was a consistently lower IFNc response or in
some cases a complete ablation of the response. The presence of
enhanced responses to some epitopes and recognition of a small
number of new epitopes in the ubiquitinated construct suggests
that some epitopes may be recognised as a consequence of gene
modification which alters antigen processing. Nevertheless the
overall impact of ubiqutinating the gag gene resulted in down-
regulation of IFNc production. Despite our transgene constructs
being mammalian codon optimised and fusion to ubiquitin
increasing proteasomal targeting, the responses conferred by
ubiquitin were reduced and seemed contradictory. However, there
are some studies where the strategy of targeting the presentation
pathways by ubiquitination has also failed [42,43] suggesting that
the outcome of targeting is largely dependent on the protein
modified. Indeed, this proposal is supported by our study in which
responses were reduced by fusion of ubiquitin to HIV gag but not
to melanin. A study investigating malaria DNA vaccines also
illustrated that two antigens from the same stage of the parasite life
cycle responded differently to strategies designed to improve their
immunogenicity [41]. The authors suggest that the difference in
targeting maybe due to the inherent natural instability of the
protein. In fact, our results illustrated that unmodified CN54 gag is
already very efficiently targeted to the proteasome (Figure 1)
suggesting that further targeting of the presentation pathway
would result in little enhancement of responses and that fusion to
ubiquitin suppressed responses. The view that fusion to ubiquitin
reduces responses is supported by experiment with the more stable
ZM96 gag where fusion to ubiquitin greatly enhances proteasomal
degradation yet results in lowering of T cells responses. The high
level of proteasomal targeting of unmodified CN54 gag, and
presumably the class I processing pathway, may explain why the
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responses were higher than those observed with ZM96. The
efficiency with which HIV-1 CN54 gag was targeted to the
proteasome was unknown at the time of transgene construct and
was based on the finding that HIV-1 ZM96 gag, which shares
90% sequence homology with HIV-1 CN54 gag, did not
efficiently target to the proteasome until the gene was ubiquiti-
nated (as shown in Figure 3). However, like the CN54 gag
transgene construct, ubiquitination of the ZM96 gag did not
Figure 6. Phenotype of CD8 cells and their expression of IFN gamma from HLA-A*0201 individuals. MoDCs from HLA-A*0201
individuals were transduced with either the non-ubiquitinated (MART 0x, hatched bar) or ubiquitinated (MART 1x, grey bar) MART construct, as well
as the dominant peptide ELAGIGILTV (peptide, open bar) as a positive control. DCs were then co-cultured with autologous naı¨ve T cells and after each
subsequent week in culture, T cells were harvested and stained with antibodies to the indicated surface markers (A). B) After 3 weeks of T cell
expansion in culture, T cells were harvested and restimulated with the dominant peptide, ELAGIGILTV, and IFNc production was determined by
intracellular cytokine staining and ELISPOT. Cells were analysed by flow cytometry, and A) box plots represent the median with upper and lower
quartiles, and whiskers represent the min and max values of 5 donors and B) shows individual donors.
doi:10.1371/journal.pone.0088327.g006
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enhance or broaden CTL responses suggesting that the reduced
responses seen with the Ub+gag constructs did not reflect excessive
proteasomal degradation. Hence, the question remains, why does
ubiquitination of the CN54 gag result in diminished IFNc
responses. It is unclear why the ubiquitination of HIV gag results
in less IFNc compared to other ubiquitinated proteins, such as
MART, considering that both constructs do result in the
production of other immune mediators. The result suggests that
ubiquitination of the HIV gag, may somehow interfere with the
signalling cascade resulting in IFNc production and requires
further investigation.
Previous work on increasing immunogenicity of target antigens
has determined CTL responses by assay of viral load, cytotoxicity
and/or IFNc production [18,40,44]. Our work has primarily
determined CTL responses by IFNc production and consequently
it is possible that we have underestimated CD8+ T cell responses
by limiting our readout system. However, we did measure 10
secreted immune modulators and among them were Granzyme A
and B which were both produced during the course of culture.
Figure 7. Expression of maturation markers on transduced moDCs. MoDCs were transduced with either the A) non-ubiquitinated (0x,
hatched bar and dotted line) or ubiquitinated (1x, grey bar and grey line) HIV-1 CN54 gag constructs or B) non-ubiquitinated (0x, hatched bar and
dotted line) or ubiquitinated (1x, grey bar and grey line) MART-1 constructs or untransduced (control, open bar). Following an overnight incubation,
DCs were then matured with LPS and IFNc for a further 24 hrs and then harvested and stained with the indicated antibodies and analysed by flow
cytometry. A) represents 9 donors, and the histogram represents one donor, B) represents 4 donors and the histogram represents one donor and box
plots represent the median with upper and lower quartiles, and whiskers represent the min and max values.
doi:10.1371/journal.pone.0088327.g007
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However, there was no discernible difference between the levels of
Granzyme A and B or in any of the immune mediators, in
supernatants from co-cultured cells stimulated with either
construct. The observation of reduced IFNc production suggests
that Ub+ gag constructs might reduce the capacity of DCs to
produce IL-12, and hence prime an optimal Th1 response.
Although we did not measure the output of IL-12 by DCs
transduced with either construct, we did investigate the effect of
transduction on DC maturation and found that the Ub+ gag
reduced the expression of the co-stimulatory and maturation
markers, CD80, CD83, HLA-DR and CD86. Engagement of
CD86 on DCs with CD28 on T cells provides T cells with the
necessary co-stimulatory signals to be readily activated [45], and
the down-regulation of the co-stimulatory and maturation markers
on DCs as a consequence of Ub+gag transduction may in part
explain why co-culture of these DCs with T cells results in lowered
IFNc production. Although our other measured immune medi-
ators showed no difference in levels between constructs, it must be
duly noted that this was measured in the supernatants of cultures
and was therefore a cumulative level of mediators. It is possible
that on a per cell basis there may have been more obvious
differences, though our main readout was IFNc production.
Nevertheless, transduction of DCs with Ub+gag resulted in
lowered expression of key surface molecules which are required
for optimal priming of T cells. Interestingly, recent studies have
shown that ubiquitin regulates CD86 expression and subsequently
DC maturation and antigen presentation [46,47] and that CD86
ubiquitination is facilitated by IL-10 [46]. The authors show that
ubiquitination of CD86 via MARCH1, an E3 ligase, down-
regulates CD86 surface expression thereby regulating immune
Figure 8. Expression of PDL1 and production of IL-10 by transduced moDCs. MoDCs were transduced with either the non-ubiquitinated
(0x, hatched bar or closed circle) or ubiquitinated (1x, grey bar or closed square) HIV-1 CN54 gag constructs or untransduced (control, open bar).
Following an overnight incubation, DCs were then matured with LPS and IFNc for a further 24 hrs. Cells and supernatants were harvested and A) cells
were stained with anti-PDL1 and analysed by flow cytometry and B) the production of IL-10 was determined by ELISA. Graph A) represents the
mean6SD of 5 donors and graph B) represents 6 individual donors.
doi:10.1371/journal.pone.0088327.g008
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responses. It is unknown whether MARCH1 plays a role in the
down-regulation of CD86 in our system, but our results suggest
that transduction of DCs with ubiquitinated gag may result in
excessive IL-10 production which in turn down-regulates CD86.
Indeed, we measured IL-10 at the time of transduction, and found
that DCs transduced with the Ub+gag construct resulted in a
higher IL-10 production which could result in ubiquitination of
CD86. This ubiquitination could be further enhanced by the
presence of exogenous ubiquitin present in the construct.
Subsequent down-regulation of CD86 would therefore result in
sub-optimal activation of T cells and hence reduced IFNc
production.
Our results show that despite previous indication that
ubiquitination increases immune responses, due diligence must
be taken when undertaking such a strategy. In fact, the choice of
antigen and its inherent stability are important factors when
considering ubiquitination as an approach to vaccine design. The
gag protein of HIV-1 strain CN54 is unstable as indicated by our
proteasomal data and therefore there may already be generation
of peptides at sufficient levels to ensure maximum responses
without the need to further increase proteasomal degradation
through fusion to the ubiquitin gene. As shown here this did not
result in an enhanced response and may have abrogated the
response by impairing dendritic cell maturation. Thus, expression
of key maturation markers on DCs could be used as a quick
determinant to elucidating the effect of ubiquitination of a protein
as a possible vaccine candidate, as well as the production of IL-10.
Our results highlight the importance of not only enhancing a T
cell response to HIV proteins, but also ensuring optimal dendritic
cell or antigen presenting cell maturation for a successful vaccine
against HIV.
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